M yocardial infarction (MI) evokes changes within the architecture of the left ventricular (LV) wall leading to chamber dilation. The matrix metalloproteinases (MMPs) are a family of endopeptidases known to degrade all components of the myocardial extracellular matrix (ECM). In experimental models of MI, gene deletion of certain MMPs or pharmacological inhibition of MMP activity directly modifies the LV remodeling process post-MI. [1] [2] [3] [4] [5] However, in clinical studies, pharmacological MMP inhibition has been associated with adverse systemic effects, which have resulted in limited clinical use. [6] [7] [8] As a result, a renewed interest in the endogenous inhibitors of MMPs, the tissue inhibitors of MMPs (TIMPs), has developed. [9] [10] [11] [12] [13] There are 4 known TIMPs, and through gene deletion studies, it has been demonstrated that a loss of TIMPmediated MMP inhibition can accelerate and exacerbate LV remodeling, particularly post-MI. 2, 11, 12 For example, TIMP-1 gene deletion in mice caused accelerated LV dilation and pump dysfunction after MI. 2 One particular TIMP, TIMP-4, has been demonstrated to have a predominant expression profile to the cardiovascular system and may likely hold relevance to the myocardial remodeling process. 12, [14] [15] [16] [17] After MI induction in animal systems, TIMP-4 levels significantly fall within the MI and border regions. 5, 16, 17 In clinical observational studies, relative plasma TIMP-4 levels were reduced for up to several months in patients after MI. 15 It is now becoming recognized that each TIMP imparts unique biological effects with respect to cellular growth, proliferation, and viability with TIMP-4 being no exception. [8] [9] [10] 13, 18, 19 Thus, restoring the balance between myocardial levels of MMPs and TIMPs, such as TIMP-4, may provide a mechanism by which to reduce adverse LV remodeling post-MI. The present study tested the central hypothesis that myocardial overexpression either through targeted viral induction of the full-length human TIMP-4 or through transgenic mediated cardiac overexpression of TIMP-4 would favorably modify the adverse LV remodeling process after MI.
Methods
This study used coronary ligation in mice to produce a reproducible MI size and predictable time-dependent changes in LV geometry and function. [1] [2] [3] 20 MI was induced in wild-type adult mice with or without targeted regional overexpression of human TIMP-4 through an adenoviral delivery approach or through transgenic construct with cardiac-restricted overexpression TIMP-4 (hTIMP-4exp). The main response variables were LV geometry and function at 5 and 21 days post-MI. These post-MI time points were chosen because these reflect the key phases of the early wound healing/remodeling process and are reflective of the more rapid trajectories for LV remodeling and dysfunction post-MI. 3, 6, 15, 17 The secondary set of measurements included indices of ECM remodeling (collagen expression and content), MMP and TIMP expression, indices of myocyte hypertrophy and apoptosis, and determinants of inflammation/fibrosis. All animals were treated and cared for in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals (Eighth Edition, Washington, DC; 2011).
Adenoviral Construct of Human Timp-4 and Myocardial Transduction
The full-length human TIMP-4 cDNA as well as that for green fluorescent protein (GFP) were cloned using an adenoviral shuttle plasmid approach, followed by transfection and purification to a final titer of 8×10 9 plaque forming units/mL using approaches described previously and fully detailed in the Methods in the Online Data Supplement. 21, 22 Using a 27-gauge needle, 10 μL of the adenoviral construct encoding GFP and the full-length human TIMP-4 (Ad-GFP-TIMP-4) or Ad-GFP only was placed in the midmyocardium. This injection approach and initial validation studies are shown in the Methods in the Online Data Supplement.
Transgenic Myocardial Overexpression of Human TIMP-4
The full-length sequence of the human TIMP-4 gene 14 was ligated to the cardiac-specific murine α-myosin heavy chain promoter 23 and established in a friend leukemia virus, strain B (FVB) as detailed in the Methods in the Online Data Supplement. The hTIMP-4exp mice demonstrated no obvious phenotypic abnormalities, were fertile, and produced viable litters.
MI Induction and Protocol
For these studies, the mice were anesthetized using isoflurane anesthesia (3% in oxygen), and a baseline echocardiogram (40 MHz ultrasonic scan head, Vevo 770, VisualSonics, Toronto, Canada) was first obtained. 3, 20, 23 After these measurements, the left anterior descending artery was exposed and ligated. For the adenoviral portion of the study, mice (C57, 2 months, equal sex distribution, n=91) were randomized in a blinded, 1:1 fashion to undergo myocardial injection of Ad-GFP-TIMP-4 or Ad-GFP within the MI region. The intraoperative mortality was 12% (hemodynamic compromise or arrhythmogenesis; n=10), and the post-MI mortality was 13% (sudden death or rupture; n=11), with no differences between the Ad-GFP-TIMP-4 and Ad-GFP groups. For the hTIMP-4exp studies, the mice (n=32) were treated in identical fashion. The intraoperative and post-MI survival was similar to the adenoviral studies (13% and 12%, respectively). For additional comparative purposes, age/time-matched FVB or hTIMP-4exp mice underwent identical LV function studies and myocardial measurements (n=6/time point). At designated post-MI time points, a second echocardiogram was performed and the LV was then removed and sectioned for morphometric and biochemical measurements.
Myocardial Morphometric and Biochemical Measurements
LV sections were stained with hematoxylin and eosin for measurement of MI size and myocyte cross-sectional area.
3,5 LV sections were also stained with picrosirius red to determine the percent area of collagen. 20, 23 LV samples were also prepared for RNA isolation for real-time polymerase chain reaction, immunoassay, and MMP zymography as detailed in the Methods in the Online Data Supplement. The mRNA levels were quantified for TIMP-4 (both human and mouse), TIMP-1, TIMP-2, and TIMP-3, collagen types I and III, transforming growth factor-β receptor-1 (TGF-βR1), discoidin domain receptor-2 (DDR2), MMP-14 (membrane-type 1 matrix metalloproteinase [MT1-MMP]), as well as an apoptotic mRNA array (Methods in the Online Data Supplement). The results were computed as a normalized (18s signal) cycle times. Substrate zymography was performed to assess the relative content of the gelatinases, MMP-2, and MMP-9.
2,3,16,17 LV myocardial extracts were also subjected to a cytokine multiplex array (Methods in the Online Data Supplement).
Fibroblast Growth and Expression With TIMP-4 Transduction
Because it has been established that TIMPs may directly affect fibroblast form and function beyond that of altering MMP activity, 8, 9, 13 murine myocardial fibroblast preparations using an outgrowth technique were prepared, 24 and Ad-GFP-TIMP-4 or Ad-GFP transduction performed (Methods in the Online Data Supplement).
Data Analysis
Response variables were compared between the groups initially using a multiway ANOVA in which the main treatment effects were Ad-GFP-TIMP-4 injection or hTIMP-4exp and the presence or absence of MI. Individual group mean comparisons were performed using pairwise Bonferroni corrections. In addition, the matched baseline and post-MI comparisons were performed using a paired t test. Comparisons to reference values were performed by a separate t test, and potential treatment effects were examined by a 2-way ANOVA followed by a Bonferroni corrected t test as appropriate. For the morphometric measurements, a Gaussian distribution was first developed to ensure adequate sampling and then subjected to ANOVA. For the apoptosis array measurements, the ΔΔ cycle time values were computed to a fold change from referent control values, and a >2-fold change was considered statistically significant. For the fibroblast studies, comparisons between treatments were performed using a paired t statistic. All statistical procedures were performed using Systat statistical software (SPSS, Chicago, IL). Results are presented as mean±SEM. Values of P<0.05 were considered statistically significant.
Results

Induction of TIMP-4 Improves LV Function and Geometry Post-MI
Representative LV long-axis echocardiographic views at baseline and key post-MI time points after injection with Ad-GFP only or Ad-GFP-TIMP-4, as well as in hTIMP-4exp mice, are shown in Figure 1A . Significant LV dilation was evident in all post-MI groups but seemed attenuated with either adenoviral or transgenic overexpression of TIMP-4. LV geometry and function for non-MI values and at the post-MI time points along with sample sizes are summarized in the Table. LV ejection fraction fell in all post-MI groups but was highest in the TIMP-4 induction groups. LV end-diastolic volume increased as a function of time post-MI but was reduced in the Ad-GFP-TIMP-4 group and reduced further in the hTIMP-4exp group. LV posterior wall thickness (at the site of the MI) and LV mass were higher in both TIMP-4 groups compared with Ad-GFP only values. An index of LV systolic function, LV velocity of shortening, was higher in both TIMP-4 groups compared with Ad-GFP only values. The temporal changes in LV geometry and function after MI as a function of TIMP-4 induction are summarized in Figure 1B . This analysis further demonstrated that with either Ad-GFP-TIMP-4 injection or hTIMP-4exp, key indices of post-MI remodeling were attenuated.
A subset of studies were performed in identical fashion in FVB strain mice at baseline and at 5 and 21 days post-MI (n=6/time point; no Ad-GFP injections). Baseline, pre-MI LV ejection fraction, and end-diastolic volumes were equivalent to those shown in the Table (66±2%, 44±4 μL, respectively) and directionally changed to the same relative degree by 21 days post-MI (28±2%, 90±6 μL, respectively, both P<0.05 versus pre-MI values). Thus, the trajectory and magnitude of the changes in LV geometry and function in both the C57 and FVB strains at these defined post-MI time points were identical in the absence of human TIMP-4 induction.
Uniform TIMP-4 Induction With Adenoviral and Transgenic Approaches
LV myocardial samples from the targeted adenoviral injection region were subjected to GFP immunoblotting at 5 and 21 days and demonstrated a uniform and consistent signal for GFP ( Figure 1C ). Immunoblotting for human TIMP-4 was performed in the hTIMP-4exp at the targeted study end points ( Figure 1C ). A clear, specific, and uniform signal for human TIMP-4 was obtained in all non-MI hTIMP-4exp samples, which increased in the hTIMP-4exp myocardium after MI.
Human-specific TIMP-4 and mouse-specific TIMP-4 mRNA were quantified by polymerase chain reaction in LV myocardial samples taken at 5 or 21 days after injection and MI induction with Ad-GFP only, Ad-GFP-TIMP-4, or in hTIMP-4exp mice ( Figure 1D ). In the Ad-GFP-TIMP-4 mice, mRNA levels significantly increased at 5 and 21 days post injection and post-MI. In the hTIMP-4exp mice, robust mRNA levels for human TIMP-4 were observed, which remained elevated at 5 and 21 days post-MI. Thus, a significant and persistent induction of specific human TIMP-4 was achieved within the targeted region with adenoviral injection and throughout the myocardium with transgenic TIMP-4 overexpression.
TIMP-4 Induction Does Not Alter MI Size, But Increases Collagen Content
MI size computed as a function of LV surface area was 37±3%, with no difference between groups. Distribution plots for LV myocyte cross-sectional area for the remote region for all groups are shown in Figure 2A . Cross-sectional area increased post-MI in all groups and was higher in the Ad-GFP-TIMP-4 group at 21 days post-MI. LV relative collagen content was computed in both the MI and remote regions ( Figure 2B ). Although collagen content was increased within the MI region as well as in the remote region in all groups, these values were higher in both TIMP-4 induction groups.
TIMP-4 Induction Alters mRNA Levels for Other ECM Regulatory Proteins
Relative myocardial mRNA levels for TIMP-1, TIMP-2, and TIMP-3 as well as the fibrillar collagens, collagen types I and III, are shown in Figure 3 . TIMP-1 levels increased at 5 days post-MI and then fell at 21 days post-MI, with no significant differences between groups. Relative TIMP-2 mRNA levels increased in the Ad-GFP-TIMP-4 and hTIMP-4exp groups at 5 and 21 days post-MI. At 21 days post-MI, TIMP-3 mRNA levels were higher in the Ad-GFP-TIMP-4 and hTIMP-4exp Values presented as mean±SEM. Effects of adenoviral construct encoding green fluorescent protein (Ad-GFP), adenoviral construct encoding GFP/full-length human tissue inhibitor of matrix metalloproteinase-4 (Ad-GFP-TIMP-4) induction, and transgenic construct with cardiac-restricted overexpression of TIMP-4 (hTIMP-4exp groups. At 5 days post-MI, increased mRNA levels for collagen I and III were equivalently increased in all groups. However, a persistent induction of collagen I and III occurred at 21 days post-MI in the hTIMP-4exp group. LV myocardial mRNA levels for MT1-MMP, DDR2, and TGF-βR1 are summarized in Figure 4 . MT1-MMP mRNA levels increased in all groups at 5 days post-MI and remained elevated at 21 days post-MI in the hTIMP-4exp group. Relative DDR2 mRNA levels appeared lower in the Ad-GFP-TIMP-4 group at 5 days post-MI, whereas DDR2 mRNA levels were increased in the hTIMP-4exp group at 21 days post-MI. TGF-βR1 mRNA levels increased in all post-MI time points in all groups but was highest in the hTIMP-4exp groups.
TIMP-4 Induction Alters Cytokine Content and Apoptotic mRNA Levels Post-MI
LV myocardial levels for specific cytokines occurred with TIMP-4 induction and are summarized in Figure 4 . Specifically, interleukin-6 (IL-6) content increased in all groups at 5 days post-MI and reduced to referent control values by 21 days post-MI. However, IL-6 levels were lower in the hTIMP-4exp group at 5 days post-MI. LV myocardial IL-10 levels were significantly reduced in the Ad-GFP-TIMP-4 group and nondetectable in the hTIMP-4exp group.
Monocyte chemoattractant protein 1 was increased at 5 days post-MI in all groups but reduced in the hTIMP-4exp group. LV myocardial expression levels for certain apoptotic genes were affected by MI and TIMP-4 induction and are shown in Figure 4 . LV myocardial B-cell leukemia/lymphoma 2 mRNA levels were higher at the non-MI and 21-day post-MI time point in the hTIMP-4exp group and were higher in the Ad-GFP-TIMP-4 group at 21 days post-MI, but this did not reach predefined statistical significance. A significant induction of apoptotic peptidase activating factor 1 and receptor (TNRSF [tumor necrosis factor receptor superfamily])-interacting serine-threonine kinase 1 occurred at 5 days post-MI in the Ad-GFP group but not in either the Ad-GFP-TIMP-4 or the hTIMP-4exp groups.
TIMP-4 Induction Reduces MMP-9 and Active MMP-2 Levels Post-MI
The latent form of MMP-9 (92 kDa) as well as the latent and active forms of MMP-2 (72/68 kDa, respectively) were identified and quantified by zymography/densitometry ( Figure 5 ). In the Ad-GFP-TIMP-4 and hTIMP-4exp groups, relative MMP-9 levels were lower post-MI. For MMP-2, the active form was reduced in both the Ad-GFP-TIMP-4 and hTIMP4exp groups post-MI. 
TIMP-4 Induction in Fibroblasts Alters Growth and Apoptotic and ECM mRNA Levels
LV myocardial fibroblasts were transduced with either Ad-GFP or Ad-GFP-TIMP-4 and yielded a uniform transduction efficiency of ≈70% with both vectors (Figure 6 ). LV fibroblast cell density, indicative of cell proliferation, was higher at 24 hours post-transduction with TIMP-4. In addition, transduction of TIMP-4 in these LV fibroblast cultures resulted in significantly higher mRNA levels for B-cell leukemia/lymphoma 2, collagen I, DDR2, and TGF-βR1 ( Figure 6 ).
Discussion
It has been clearly established in both animal models and clinical studies that an altered balance in MMPs and TIMPs occurs after MI, which would favor myocardial ECM degradation and facilitate adverse post-MI remodeling. systemic pharmacological approaches to inhibit MMP activity demonstrated favorable effects on post-MI remodeling in animal studies, [1] [2] [3] 5 concerns regarding dosing strategies, systemic side effects, and equivocal initial clinical results have limited progress on this approach. [6] [7] [8] Thus, strategies to modulate MMP activity on a region-and tissue-specific manner in the context of post-MI remodeling may hold greater clinical translational potential. Under normal conditions, TIMP-4 is highly expressed within the cardiovascular system, particularly the myocardium. 14, 16, 17 However, clinical and animal studies have demonstrated a relative reduction in TIMP-4 levels in the early post-MI period. [15] [16] [17] The present study addressed this issue using 2 different but complementary strategies. First, myocardial injection of a replication adenoviral construct containing the full-length human TIMP-4 sequence and a reporter protein GFP at the time of MI induction in mice was performed and compared with mice with myocardial injection of the identical adenoviral construct but only encoding GFP. Second, MI was induced in transgenic mice with cardiac-specific overexpression of TIMP-4. The significant findings of this study were 3-fold. First, a robust expression of TIMP-4 could be achieved through targeted adenoviral injections at 5 and 21 days post-MI, which resulted in favorable effects on LV function and geometry in this post-MI period. Second, hTIMP-4exp provided similar protective effects in terms of reducing post-MI LV dilation and dysfunction. Third, augmenting myocardial TIMP-4 levels in the early post-MI period resulted in reduced elaboration of MMP-9 and reduced activational state of MMP-2. Taken together, this is the first study to demonstrate that myocardial augmentation of TIMP-4, either through an adenoviral delivery or through a transgenic approach, can alter the early course of post-MI remodeling.
TIMP-4 as a Potential Therapeutic Strategy
Using different transgenic constructs, past studies have demonstrated that the deletion of specific MMP/TIMP genes can alter the course of pathological LV remodeling. [1] [2] [3] [4] 11, 12 For example, MMP-2 gene deletion in mice caused a relative reduction in the degree of LV remodeling post-MI and was associated with increased survival. 1 Conversely, gene deletion of TIMPs, which bind to the active form of MMPs, have been demonstrated to exacerbate adverse LV remodeling. 2, 11, 12 For example, TIMP-1 gene deletion accelerates LV dilation in mice post-MI, 2 whereas TIMP-3 gene deletion causes LV dilation and dysfunction with aging or pressure overload. 13 In addition to these transgenic studies, pharmacological MMP inhibition has also been demonstrated to alter the course of LV remodeling post-MI. [1] [2] [3] 5, 17 However, although these transgenic and pharmacological approaches demonstrated a cause-effect relation between changes in the normal MMP-TIMP balance and adverse LV myocardial remodeling, these approaches entail affecting MMP activity throughout the entire organism. In the case of pharmacological MMP inhibition, concern for systemic side effects have tempered clinical development of this approach for treating adverse LV myocardial remodeling. [6] [7] [8] 25 The present study demonstrated that altering a determinant of MMP activity in a localized and time-specific manner reduced the degree of LV dilation post-MI, reduced the degree of LV wall thinning within the MI region, and improved LV pump function. These favorable effects of either targeted gene delivery or by cardiac-restricted overexpression of TIMP-4 on the post-MI remodeling process are similar to those achieved by either a global transgenic approach or through broad-spectrum, systemically delivered MMP inhibition. [1] [2] [3] [4] [5] 17 Thus, one of the important findings of this study is that localized modulation of the MMP/TIMP system can impart beneficial effects on the post-MI remodeling process and thereby provides a potential future therapeutic direction.
Rationale for Targeting TIMP-4
A critical control point for net MMP activity is through forming noncovalent complexes with TIMPs. 9, 18, 26 However, each TIMP may also have unique characteristics and biological functions that may be relevant to the myocardial remodeling process. [8] [9] [10] [11] [12] [13] 18, 19, 26 First, it seems that TIMP-1 binds with less efficiency to the membrane-type MMPs, which have been shown to be upregulated in human heart failure and with ischemia-reperfusion. 18, 26 Past studies from this laboratory have demonstrated that MT1-MMP induction can accelerate adverse post-MI remodeling. 27 In kinetic studies, TIMP-4 binds with high affinity and thus is a potent inhibitor of this transmembrane matrix protease. 18, 19 It has been demonstrated that TIMP-2 forms a unique complex with pro-MMP-2 and MT1-MMP, which in turn can facilitate MMP-2 activation. 18, 26 Thus, induction of TIMP-4 as achieved in the present study, would likely inhibit this activation cascade and reduce relative active MMP-2 levels. Clinical studies of post-MI remodeling and large animal studies have reported that TIMP-4 levels are notably reduced or actually extinguished. 2, 16, 17 Finally, TIMP-4 gene deletion has been shown to exacerbate post-MI remodeling, providing further impetus for the studies executed herein.
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Cellular and Extracellular Effects of TIMP-4
It is unlikely that the relative improvement in LV function and geometry achieved by TIMP-4 augmentation was attributable to significant myocardial salvage or substantial differences in cardiac myocyte viability because a uniform and consistent MI size was achieved in this permanent coronary occlusion model. However, TIMP-4 augmentation in this post-MI model did seem to increase myocardial growth of residual viable myocardium as measured by LV mass, wall thickness, and myocyte cross-sectional area. Furthermore, the antiapoptotic gene Bcl2 was higher at a later post-MI time point with TIMP-4 induction. Indices of inflammation, such as IL-6, IL-10, and monocyte chemoattractant protein 1, were increased post-MI but were suppressed to the greatest degree with transgenic TIMP-4 overexpression. The adenoviral injection approach may have induced a localized inflammatory response, which was not present with the transgenic approach for TIMP-4 overexpression. Taken together, these findings suggest that myocardial TIMP-4 augmentation did not adversely affect myocyte growth, viability, or local inflammatory pathways. The present study demonstrated that TIMP-4 induction altered MMP-9 levels post-MI, which are robustly synthesized and expressed by neutrophils and other inflammatory cells. 18, 26 This further supports the observations that TIMP-4 augmentation likely reduced local inflammatory pathways. Interestingly, myocardial TIMP-4 deletion has been reported to be associated with enhanced neutrophil infiltration, 12 suggesting that TIMP-4 may serve to stabilize the myocardial matrix and thereby impede inflammatory cell migration with myocardial injury.
The potential effects of TIMP-4 augmentation on fibroblast growth and viability were addressed through both in situ and in vitro approaches. Myocardial expression of DDR2, which can be used as a surrogate marker for fibroblasts, 28 was increased at 5 days post-MI in all groups but was further increased at 21 days post-MI with transgenic cardiac TIMP-4 overexpression. The transgenic model caused elevated TIMP-4 levels across the entire myocardium, whereas targeted adenoviral injections would only yield a regional increase specifically within the MI. Thus, the elevated DDR2 levels with transgenic overexpression of TIMP-4 likely drove fibroblast proliferation/transdifferentiation throughout both the MI and remote myocardial regions. The present study identified that coupled with the increased DDR2 mRNA levels, TGF-βR1 levels were also increased in the transgenic overexpression of TIMP-4 post-MI. Enhanced TGF signaling can induce fibroblast proliferation and transdifferentiation. 28, 29 Using murine cardiac fibroblast cultures, the present study demonstrated that transduction of TIMP-4 increased fibroblast proliferation, which was accompanied by changes in key determinants of apoptosis and ECM synthesis. These effects of TIMP-4 induction on fibroblast proliferation are in keeping with the findings reported by Lovelock et al. 13 Although extrapolation of these in vitro studies to the in vivo post-MI context must be done with caution, these observations support the postulate that myocardial induction of TIMP-4 affected fibroblast number and phenotype, which in turn may have played a contributory role in attenuating ECM turnover, increased ECM stability, and hence reduced adverse LV remodeling.
Several measures of ECM remodeling were undertaken in the present study. First, myocardial fibrillar collagen expression increased markedly at 5 days post-MI, and then consistent with the wound healing response, fell to within normal limits at 21 days post-MI. Although myocardial TIMP-4 induction through a targeted adenoviral approach did not alter fibrillar collagen expression, fibrillar collagen expression remained elevated with cardiac-restricted overexpression of TIMP-4. However, collagen mRNA levels alone may not necessarily imply a net gain in collagen content. Morphometric measurements demonstrated that relative fibrillar collagen content was increased within both the MI and remote regions with either adenoviral mediated or by transgenic induction of TIMP-4. Although the elevated myocardial collagen content did not seem to affect LV geometry and function negatively, the longer term consequences of higher collagen content on myocardial structure and function with TIMP-4 augmentation remain to be determined.
Conclusions
It must be recognized that the adenoviral injections were performed at the time of MI induction, and peak expression levels of TIMP-4 can be variable in the post-MI observation period. To address this limitation and to buttress the observations made by TIMP-4 adenoviral delivery, an entirely different approach and construct was integrated into the study design by the use of cardiac-restricted overexpression of human TIMP-4. This provided a much more robust increase in TIMP-4 levels, and hence a more pronounced effect on LV remodeling and ECM structure was observed. In addition, this transgenic construct in turn has limitations in terms of a restricted pattern of expression to primarily cardiac myocytes and persistent expression rather than temporal specificity to the MI time point. Nevertheless, the similar directional changes in LV remodeling, function, and ECM structure observed in both forms of TIMP-4 augmentation provide clear support that selective myocardial induction of TIMP-4 was the primary mechanism for these effects post-MI. The myocardial induction of TIMP-4 either through adenoviral transduction or through transgenesis did seem to influence other endogenous TIMP levels. First, endogenous mouse levels of TIMP-4 were reduced, particularly in the cardiac-restricted human TIMP-4 construct. This would suggest that some feedback mechanism occurred with persistent and significant overexpression of TIMP-4. Second, myocardial induction of TIMP-4 through either approach seemed to increase myocardial expression of TIMP-2 and TIMP-3, albeit to a modest degree, in the late post-MI period. Thus, whether and to what extent myocardial induction of TIMP-4 and the subsequent modification of other TIMP types may have played a role in the post-MI remodeling process remains to be established.
In conclusion, this study is the first to demonstrate that targeted and specific myocardial induction of TIMP-4 favorably altered post-MI remodeling. These findings provide a proof of concept that regional modulation of MMP/TIMP pathways, rather than through systemic or global approaches, can favorably affect LV form and function in the post-MI context.
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